Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

Purpose: This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab. Experimental Design: Seventy recurrent/metastatic epithelial ovarian cancer patients were enro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2008-11, Vol.14 (22), p.7554-7563
Hauptverfasser:	SCHULTHEIS, Anne M, LURJE, Georg, HIRTE, Hal, FLEMING, Gini, ROMAN, Lynda, LENZ, Heinz-Josef, RHODES, Katrin E, WU ZHANG, DONGYUN YANG, GARCIA, Agustin A, MORGAN, Robert, GANDARA, David, SCUDDER, Sidney, OZA, Amit
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Cyclophosphamide - administration & dosage Disease-Free Survival Drug Resistance, Neoplasm - genetics Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Kaplan-Meier Estimate Medical sciences Metronomic Chemotherapy Ovarian Cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality Pharmacology. Drug treatments Pilot Projects Polymerase Chain Reaction Polymorphism, Restriction Fragment Length Polymorphism, Single Nucleotide Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!